Probenecid for use in treating epileptic diseases, disorders or conditions

Patent metadata

Field	Value
Publication number	US-12318358-B2
Application number	US-201816630114-A
Country	US
Kind code	B2
Filing date	Jul 13, 2018
Priority date	Jul 13, 2017
Publication date	Jun 3, 2025
Grant date	Jun 3, 2025

Abstract

Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

First claim

The invention claimed is:

1. A method for treating focal epilepsy in a human subject in need thereof , said focal epilepsy being characterized by an occurrence of spontaneous and recurrent focal seizures, the method comprising administering to the human subject a pharmaceutical composition consisting essentially of probenecid or a pharmaceutical acceptable salt thereof, wherein probenecid or the pharmaceutical acceptable salt thereof controls focal seizures in said human subject, and wherein probenecid or the pharmaceutical acceptable salt thereof is the only therapeutic agent administered to said human subject.

2. The method according to claim 1 , wherein the focal epilepsy is selected from the group consisting of familial epilepsy, genetic epilepsy, structural/metabolic epilepsy and epilepsies with unknown cause.

3. The method according to claim 1 , wherein the focal epilepsy is brain tumor-related epilepsy.

4. The method according to claim 1 , wherein the focal epilepsy is a malformation of cortical development (MCD)-related epilepsy.

5. The method according to claim 1 , wherein the focal epilepsy is a neurodegenerative-related epilepsy.

6. The method according to claim 1 , wherein the focal epilepsy is a dysimmune epilepsy.

7. The method according to claim 1 , wherein the human subject is suffering from a treatment-resistant focal epilepsy.

8. The method according to claim 1 , wherein said human subject is a child.

9. The method according to claim 1 , wherein said human subject is an adult.

10. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered to the human subject at a dose ranging from 1 mg/kg/day to 100 mg/kg/day.

11. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered orally or by injection.

12. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is comprised within a pharmaceutical composition also comprising a pharmaceutically acceptable carrier or diluent.

13. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is comprised within a medicament.

Assignees

• Paris Sciences Et Lettres—Quartier Latin
• Centre Nat Rech Scient
• Inst Nat Sante Rech Med
• Univ Sorbonne
• Aphp Assist Publique—Hopitaux De Paris
• Commissariat A Lenergie Atomique Et Aux Energies Alternatives Cea
• Univ Paris
• Paris Sciences Et Lettres
• Aphp Assist Publique Hopitaux De Paris
• Univ Paris Cite

Inventors

• Rouach Nathalie
• Dossi Eléna
• Huberfeld Gilles

Classifications

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61K31/195 Primary

  having an amino group · CPC title